Xarelto

Type: Product
Name: Xarelto
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

New treatments help seniors live longer

The latest prescription drugs, surgeries, medical procedures and high-tech devices are helping seniors to live longer, healthier lives.Dr. Panayiotis Tsitouras, an OU Physicians’ geriatrician, said the proper approaches toward healthier aging include ... [Published NewsOK.com - Oct 18 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 2 reports

Recent Purchase: Johnson & Johnson

By Investing Doc :Johnson & Johnson (NYSE: JNJ ) reported third quarter revenues and earnings that mildly exceeded my expectations , and increased its earnings-per-share guidance for the remainder of the year. The results and guidance drive a very small ... [Published BioPortfolio - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Johnson & Johnson's net earnings up by 59% in Q3

Johnson & Johnson's net earnings has taken quantum jump of 59 per cent during the third quarter ended September 2014 and touched to $4,749 million as against $2,982 million in the corresponding period of last year. Its worldwide sales of pharmaceutical, ... [Published PharmaBiz - Oct 17 2014]
First reported Oct 16 2014 - Updated Oct 16 2014 - 1 reports

Bayer Said to Face US Litigation Over Xarelto Side Effects

Bayer soon may find itself regretting its decision to sell its plastics business and become a pure life science player. According to international press reports, the German group's anti-coagulant Xarelto is now in the crosshairs of the US class action ... [Published CHEManager - Oct 16 2014]
First reported Oct 15 2014 - Updated Oct 15 2014 - 1 reports

The Key Drivers For Johnson & Johnson

Johnson & Johnson ( JNJ ) is the world’s largest maker of healthcare products. It reported its third quarter earnings on October 14, exceeding analysts’ expectations by posting revenue worth $18.5 billion, a 5% jump compared to the same quarter last year. ... [Published Guru Focus - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

Hep. C medication boosts J&J earnings

Share this article: Hepatitis C medication Olysio (simeprevir) boosted Johnson & Johnson's third-quarter pharmaceutical sales, powering an 18% increase in worldwide pharma revenue, to $8.3 billion, compared to the same period last year. The drugmaker ... [Published Medical Marketing And Media - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 1 reports

Johnson & Johnson - Appealing Amidst Continued Growth And Fair Valuation

Summary Johnson & Johnson posts solid third quarter results. Growth was driven by the pharmaceutical segment in particular, resulting in appealing growth amidst a fair valuation. The strong dividend hike, track record and strong balance sheet are additional ... [Published Seeking Alpha - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 15 2014 - 2 reports

J&J raises outlook on Q3 beat

The medical giant's earnings, ex items, rose 10% to $1.50 a share, beating analysts' estimates by 5 cents. Sales climbed 5% to $18.47 bil, $90 mil ahead of consensus. Johnson & Johnson (JNJ) raised its full-year EPS guidance to $5.92-$5.97, on the high ... [Published Yahoo! Finance - Oct 15 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Mealey's PI/Product Liability - MDL Sought For Xarelto Uncontrolled Bleeding Cases

WASHINGTON, D.C. - Plaintiffs in 21 cases on Oct. 9 asked a federal judicial panel to centralize lawsuits alleging that the manufacturer and distributor of the anticoagulant Xarelto failed to warn doctors and patients of the risk of severe bleeding and ... [Published Mealey - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

UPDATE: Johnson & Johnson Posts Better-Than-Expected Q3 Earnings, Lifts Full-Year Forecast

Johnson & Johnson (NYSE: JNJ) reported better-than-expected third-quarter earnings and lifted its earnings forecast for the full year.The New Brunswick, New Jersey-based company reported a quarterly profit of $4.75 billion, or $1.66 per share, versus ... [Published Benzinga.com - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Johnson & Johnson Quarterly Profit Rises on Sale of Unit

Johnson & Johnson (JNJ) , the world’sbiggest maker of health-care products, said third-quarter profitsoared on the sale of its Ortho Clinical Diagnostics unit. Thecompany raised its full-year forecast.Net income rose 59 percent to $4.75 billion, or $1.66 ... [Published Bloomberg - Oct 14 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

J&J Worldwide Pharama Sales Growth YoY

Remicade Sales Grew From $1,689M To $1,782M, 7.1% Xarelto Sales Grew From $246M To $414M, 68.3% Stelara Sales Grew From $543M To $370M, 46.8% Olysio/Sovriad $796M Velcade Sales Fells From $404M To $389M, Decline Of 3.7% Prezista Sales Grew From $410M ... [Published Benzinga.com - Oct 14 2014]
Entities: Sales, Prezista, Stelara, Velcade

Quotes

"It's certainly better to delight than disappoint, and so the number that's out there I think is a number that certainly is one that we have confidence we can beat" Abbvie chairman and CEO Richard Gonzalez said during the company's first quarter earnings call last week
"We plan to remain competitive in the hepatitis C category and we will work with payers to maintain access for Olysio in the marketplace."
"Our strong third-quarter performance reflects the continued success of our new products and the strength of our core business. We are making deliberate portfolio choices, positioning us well for achieving our near-term priorities and our long-term growth drivers" said Alex Gorsky, chairman and chief executive
"The core drugs are doing well, with a lot of strength from newer brands, and that signifies a healthy environment for pharmaceutical stocks" Conover said

More Content

All (168) | News (144) | Reports (0) | Blogs (20) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Re: Dabigatran: how the drug company withheld i... [Published British Medical Journal - 10 hours ago]
Portola Pharma signs supply pact with Lonza for... [Published PharmaBiz - Oct 18 2014]
New treatments help seniors live longer [Published NewsOK.com - Oct 18 2014]
Recent Purchase: Johnson & Johnson [Published BioPortfolio - Oct 17 2014]
Recent Purchase: Johnson & Johnson [Published Seeking Alpha - Oct 17 2014]
Johnson & Johnson's net earnings up by 59% in Q3 [Published PharmaBiz - Oct 17 2014]
AbbVie Kills Shire Merger, But Door Opens for B... [Published TheStreet.com - Oct 17 2014]
AbbVie Kills Shire Merger, But Door Opens for B... [Published The Street Latest - Oct 17 2014]
Portola Pharmaceuticals Announces Commercial Su... [Published Virtual Strategy Magazine - Oct 16 2014]
Portola Pharmaceuticals : Announces Commercial ... [Published 4 Traders - Oct 16 2014]
Bayer Said to Face US Litigation Over Xarelto S... [Published CHEManager - Oct 16 2014]
The Key Drivers For Johnson & Johnson [Published Guru Focus - Oct 15 2014]
A Review Of Gilead's Harvoni, And Competitive C... [Published Seeking Alpha - Oct 15 2014]
Questions raised on longevity of Olysio driving... [Published PMLive - Oct 15 2014]
J&J raises outlook on Q3 beat [Published Yahoo! Finance - Oct 15 2014]
Hep. C medication boosts J&J earnings [Published Medical Marketing And Media - Oct 14 2014]
Mealey's PI/Product Liability - MDL Sought For ... [Published Mealey - Oct 14 2014]
Johnson & Johnson - Appealing Amidst Continued ... [Published Seeking Alpha - Oct 14 2014]
Johnson & Johnson third-qtr results beat analys... [Published Pharma Letter - Oct 14 2014]
Pharmaceutical Sales Highlight A Strong Third Q... [Published Seeking Alpha - Oct 14 2014]
JOHNSON & JOHNSON : J&J beats forecasts, helped... [Published 4 Traders - Oct 14 2014]
J&J ups 2014 outlook again on strong Q3 [Published Pharma Times - Oct 14 2014]
UPDATE 2-J&J beats forecasts, helped by hepatit... [Published CNBC - Oct 14 2014]
3 Dividend Stocks to Buy If the Market Crashes [Published Motley Fool - Oct 14 2014]
Johnson & Johnson Lifts Outlook Again As Q3 Res... [Published RTTNews.com - Oct 14 2014]
UPDATE: Johnson & Johnson Posts Better-Than-Exp... [Published Benzinga.com - Oct 14 2014]
J+J earnings jump on higher sales [Published Business Spectator - Oct 14 2014]
Johnson & Johnson Quarterly Profit Rises on Sal... [Published Bloomberg - Oct 14 2014]
J&J Worldwide Pharama Sales Growth YoY [Published Benzinga.com - Oct 14 2014]
Johnson & Johnson Reports 2014 Third-Quarter Re... [Published TickerTech.com - Oct 14 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Xarelto (Acute Coronary Syndrome) - Forecast an... [Published PR Newswire: Entertainment & Media - Sep 29 2014]
   NEW YORK, Sept. 29, 2014 /PRNewswire/ -- Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023SummaryGlobalData has released its new PharmaPoint Drug Evaluation report, "Xarelto (Acute Coronary Syndrome) - Forecast and Market... ...
Research and Markets: Xarelto (rivaroxaban) for... [Published Business Wire Professional Services News - Sep 24 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q9t8mn/xarelto_acute) has announced the addition of the "Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" report to their offering. The ...
Eliquis And Xarelto, Like Pradaxa, Linked To Se... [Published Drug Injury Watch - Sep 05 2014]
Hemorrhages And Gastrointestinal (GI) Bleeds Are Eliquis And Xarelto Side Effects That Can Cause Deaths (Posted by Tom Lamb at DrugInjuryWatch.com ) Eliquis and Xarelto are new anticoagulants, i.e., blood thinners, that -- unlike Coumadin ...
ESC: Xarelto Safe for Cardioverting Afib [Published MedPageToday.com - medical news plus CME for ph ... - Sep 02 2014]
BARCELONA (MedPage Today) -- Switching atrial fibrillation patients awaiting elective cardioversion to rivaroxaban (Xarelto) was as safe as warfarin in that setting. ...
Once-Daily Xarelto® from Bayer Effective and We... [Published Bayer Corporate News - Sep 02 2014]
X-VeRT is the first prospective study of a novel oral anticoagulant in patients with atrial fibrillation who undergo cardioversion / X-VeRT provides important information on the utility and practical advantages of Xarelto in early and delayed cardioversion ...
1 2 3 4

Press Releases

sort by: Date | Relevance
Keller Rohrback L.L.P. Investigates Life-Threat... [Published GlobeNewswire: Acquisitions News - Aug 26 2014]
Keller Rohrback L.L.P. Investigates Allegations... [Published GlobeNewswire: Acquisitions News - Jul 23 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.